CMClaudia Maximo

Claudia Maximo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claudia Maximo has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Laboratory and genetic characteristic associated with gallbladder-related outcomes in sickle cell disease in Brazil: results from the REDS-III multicenter cohort study

    by André Rolim Belisário, André Rolim, Mina Cintho Ozahata, Isabel Cristina Gomes Moura, Carolina Miranda, Anna Bárbara Carneiro-Proietti, Ester Cerdeira Sabino, Alessandra Ferraz, Cláudia Máximo, Cláudia, et al.

    Sickle cell disease (SCD) is a hereditary disorder characterized by HBB variants, leading to chronic hemolytic anemia and vaso-occlusion. Hepatobiliary complications, including cholelithiasis, are common but underreported. This study investigated the rates and risk factors for cholelithiasis, cholecystitis, and cholecystectomy in a large Brazilian SCD cohort. Data from 2,778 individuals across six referral centers in the REDS-III Brazilian SCD cohort were analyzed. Clinical, laboratory, and genetic data were obtained retrospectively at enrollment and prospectively during follow-up. Gallbladder-related outcomes were assessed through medical records and imaging. Whole-genome sequencing was performed via the TOPMed program. Genome-wide association analyses used logistic mixed models adjusted for age, sex, genotype, and the first 10 principal components. Cholelithiasis, cholecystitis, and cholecystectomy occurred in 35.9%, 25.1%, and 10.6% of participants, respectively. Indirect bilirubin was consistently associated with all outcomes, while associations with other laboratory variables varied by genotype. Genetic analyses confirmed associations between UGT1A1 variants and bilirubin levels and identified genome-wide associations with cholecystectomy. Novel loci, including FER1L6, LRFN5, and SDK2, were also implicated. These findings indicate a high burden of gallbladder-related disease in Brazilian individuals with SCD and highlight both established and novel genetic pathways that may inform risk stratification and preventive strategies.


  • Open Access

    Outcomes and vaccination patterns against COVID-19 in a cohort of sickle cell disease patients in the state of Rio de Janeiro

    by Claudia de Alvarenga Maximo, Jorge Francisco da Cunha Pinto, Fabiana Canedo Pinto, Patrícia Brasil


  • Open Access

    Human genetics implicates a BACH2-NRF2 axis in fetal hemoglobin activation

    by Chun-Jie Guo, Uma P. Arora, Wanying Xu, Xiaoheng Cheng, Liam D. Cato, Rick Li, Henry Y. Lu, Andrew J. Lee, Fulong Yu, Gaurav Agarwal, et al.

    Human genetic studies have identified key regulators of fetal hemoglobin (HbF) expression, including BCL11A, resulting in therapeutic advances. Yet the mechanisms by which HbF expression is activated remain incompletely understood. Here, we conduct a multi-ancestry genome-wide association study of HbF levels in 28,237 individuals that identifies 131 conditionally-independent associations across 12 genomic regions. In one previously uncharacterized associated region, the high-HbF-linked causal variant, rs1010474-C, reduces BACH2 expression and elevates HbF levels. Direct perturbation or inhibition of BACH2 elevates HbF expression. Mechanistically, BACH2 restrains activation of the HbF-encoding γ -globin genes, while loss of BACH2 enhances NRF2 chromatin occupancy and promotes activation foci formation at the γ -globin genes. BACH2 and NRF2 binding motifs in the γ -globin promoters, while overlapping, can be selectively edited to activate or repress γ -globin, respectively, and function independently of BCL11A. These findings illustrate how human genetic variation continues to advance our knowledge of therapeutically-relevant regulatory mechanisms underlying HbF expression.


  • Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort study

    by André Rolim Belisário, Ana Cristina Simões e Silva, Isabel Cristina Gomes Moura, Anna Bárbara Carneiro-Proietti, Ester Cerdeira Sabino, Paula Loureiro, Cláudia Máximo, Miriam V. Flor-Park, Daniela de Oliveira Werneck Rodrigues, Mina Cintho Ozahata, et al.

    Chronic kidney disease (CKD) has a significant impact on sickle cell disease (SCD) morbidity and mortality. Early identification of individuals at highest risk of developing CKD may allow therapeutic intervention to prevent worse outcomes. This study aimed to evaluate the prevalence and risk factors for reduced estimated glomerular filtration rate (eGFR) among adults with SCD in Brazil. Participants in the REDS-III multicenter SCD cohort with more severe genotypes aged ≥ 18 years with at least two serum creatinine values were analyzed. The eGFR was calculated using the Jamaica Sickle Cell Cohort Study GFR equation. The eGFR categories were defined according to the K/DOQI. Participants with eGFR ≥ 90 were compared to those with those with eGFR < 90. Among the 870 participants, 647 (74.4%) had eGFR ≥ 90, 211 (24.3%) had eGFR 60 to 89, six (0.7%) had eGFR 30 to 59, and six (0.7%) had ESRD. Male sex (OR: 37.3; 95%CI: 22.4–65.1), higher age (OR: 1.04; 95%CI: 1.02–1.06), higher diastolic blood pressure (OR: 1.03; 95%CI: 1.009–1.06), lower Hb (OR: 0.80; 95%CI: 0.68–0.93), and lower reticulocytes (OR: 0.94; 95%CI: 0.89–0.99) levels were independently associated with eGFR < 90. There was a trend towards higher odds of death in participants with eGFR < 90 (OR: 1.8; 95%CI: 0.95–3.32; p = 0.065). In turn, participants with eGFR < 60 had a 12.2 (95%CI: 2.1–96.9) times higher odds for death when compared to those with eGFR ≥ 60. In this study, eGFR < 90 was observed in one-quarter of adults. Older age, male sex, higher diastolic blood pressure, lower hemoglobin, and lower reticulocyte levels were associated with occurrence of eGFR < 90. Estimated GFR < 60 increased the risk of mortality.


  • Open Access

    Is Severity Score Associated With Indication for Hematopoietic Stem Cell Transplantation in Individuals With Sickle Cell Anemia?

    by Miriam V. Flor-Park, Mina Cintho Ozahata, Isabel Cristina Gomes Moura, Paula Blatyta, Shannon Kelly, Claudia di Lorenzo Oliveira, Ligia Capuani, André Rolim Belisário, Anna B.F. Carneiro-Proietti, Aderson S. Araujo, et al.


  • Open Access

    Clonal hematopoiesis in sickle cell disease

    by L. Alexander Liggett, Liam D. Cato, Joshua S. Weinstock, Yingze Zhang, Seyed Mehdi Nouraie, Mark T. Gladwin, Melanie E. Garrett, Allison Ashley-Koch, Marilyn J. Telen, Brian Custer, et al.

    Curative gene therapies for sickle cell disease (SCD) are currently undergoing clinical evaluation. However, the occurrence of several myeloid malignancy cases in these trials has prompted safety concerns. Individuals with SCD are predisposed to myeloid malignancies, but the underlying causes remain undefined. Clonal hematopoiesis (CH) is a pre-malignant condition that also confers significant predisposition to myeloid cancers. While it has been speculated that CH may play a role in SCD-associated cancer predisposition, no data addressing this issue have been reported. Here, we leverage 74,190 whole-genome sequences to robustly study CH in SCD. While we have sufficient power to detect increased rates of CH, we find no variation in rate or clone properties between individuals affected by SCD and controls. These results should help guide ongoing efforts that seek to better define the risk factors underlying myeloid malignancy predisposition in SCD and help ensure that curative therapies can be more safely applied.


  • Open Access

    Association of HIV infection with clinical and laboratory characteristics of sickle cell disease

    by André Rolim Belisário, Paula F. Blatyta, Diana Vivanco, Claudia Di Lorenzo Oliveira, Ester Cerdeira Sabino, Cesar de Almeida-Neto, Paula Loureiro, Sheila de Oliveira Garcia Mateos, Miriam V. Flor-Park, Daniela de Oliveira Werneck Rodrigues, et al.

    Background: Sickle cell disease (SCD) is a multisystem disorder characterized by a wide spectrum of clinical manifestations and severity. Studies investigating potential effects of co-morbid human immunodeficiency virus (HIV) and SCD have produced conflicting results, and additional investigations are needed to elucidate whether the interaction between the two disease states might impact both HIV and SCD clinical outcomes. The association of HIV infection with clinical and laboratory characteristics of patients with SCD was assessed. Methods: This nested case-control study included individuals with SCD with HIV treated at six Brazilian SCD centers. Clinical and laboratory data were abstracted from medical records. HIV positive participants were compared to age, gender, center, and SCD genotype matched HIV negative participants (ratio 1:4). Individual clinical outcomes as well as a composite outcome of any SCD complication and a composite outcome of any HIV-related complication were compared between the two groups. Results: Fifteen HIV positive participants were included, 12 (80%) alive and 3 (20%) deceased. Most of the HIV positive patients had HbSS (60%; n = 9), 53% (n = 8) were female, and mean age was 30 ± 13 years. The frequency of individual SCD complications of acute chest syndrome/pneumonia, sepsis/bacteremia, pyelonephritis, ischemic stroke, hemorrhagic stroke, abnormal transcranial Doppler (TCD), and pulmonary hypertension was higher in HIV positive participants when compared to HIV negative, although analyzed individually none were statistically significant. HIV positive participants had significantly higher risk of any SCD complication and of a composite HIV-related complication compared to the HIV negative group (HR = 4.6; 95%CI 1.1–19.6; P = 0.04 and HR = 7.7; 95%CI 1.5–40.2; P = 0.02, respectively). There was a non-significant trend towards higher risk of any infections in participants with HIV positive (HR = 3.5; 95%CI 0.92–13.4; P = 0.07). Laboratory parameters levels were not significantly different in individuals with and without HIV. Conclusions: In summary, our study in SCD patients shows that those with HIV have an increased risk of any SCD complication and HIV-related complications, as well as a suggestive but not significantly increased risk of infections.


  • Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics

    by André R. Belisário, Anna B. Carneiro-Proietti, Ester Cerdeira Sabino, Aderson Araújo, Paula Loureiro, Cláudia Máximo, Miriam V. Flor-Park, Daniela D.O.W. Rodrigues, Mina Cintho Ozahata, Christopher McClure, et al.

    We described the clinical, laboratory and molecular characteristics of individuals with Hb S (HBB: c.20A>T)/β-thalassemia (Hb S/β-thal) participating in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) Brazil Sickle Cell Disease cohort. HBB gene sequencing was performed to genotype each β-thal mutation. Patients were classified as Hb S/β0-thal, Hb S/β+-thal-severe or Hb S/β+-thal based on prior literature and databases of hemoglobin (Hb) variants. Characteristics of patients with each β-thal mutation were described and the clinical profile of patients grouped into Hb S/β0-thal, Hb S/β+-thal and Hb S/β+-thal-severe were compared. Of the 2793 patients enrolled, 84 (3.0%) had Hb S/β0-thal and 83 (3.0%) had Hb S/β+-thal; 40/83 (48.2%) patients with Hb S/β+-thal had mutations defined as severe. We identified 19 different β-thal mutations, eight Hb S/β0-thal, three Hb S/β+-thal-severe and eight Hb S/β+-thal. The most frequent β0 and β+ mutations were codon 39 (HBB: c.118C>T) and IVS-I-6 (T>C) (HBB: c.92+6T>C), respectively. Individuals with Hb S/β0-thal had a similar clinical and laboratory phenotype when compared to those with Hb S/β+-thal-severe. Individuals with Hb S/β+-thal-severe had significantly lower total Hb and Hb A levels and higher Hb S, white blood cell (WBC) count, platelets and hemolysis markers when compared to those with Hb S/β+-thal. Likewise, individuals with Hb S/β+-thal-severe showed a significantly higher occurrence of hospitalizations, vaso-occlusive events (VOE), acute chest syndrome (ACS), splenic sequestration, blood utilization, and hydroxyurea (HU) therapy.


  • Quality of life in pre-adolescent children with sickle cell disease in Brazil

    by Claudia Di Lorenzo Oliveira, Shannon Kelly, Cesar de Almeida-Neto, Anna Barbara Carneiro-Proietti, Fabiana Chagas Camargos Piassi, Tassila Salomon, Miriam V. Flor-Park, Claudia Maximo, Daniela Werneck Rodrigues, Rosimere Afonso Mota, et al.

    Sickle cell disease (SCD) affects more than 13 million people and can have a significant impact on the quality of life (QoL) of those persons. We performed a cross-sectional study to evaluate the QoL in SCD children 8-12 years old enrolled from November 2014 to March 2016 in a large multicenter cohort study in Brazil. The PedsQL (TM) SCD Module was used to evaluate QoL in 412 children from six Brazilian health centers. The mean age of participants was 10.5 years and 193(46.7%) were women. The mean global score was 60.7, with a Cronbach ' s alpha of 0.92. There were significant differences in socioeconomic demographics and treatments among participants at the six centers, but age, income, SCD genotype, and use of hydroxyurea did not significantly affect the QoL scores. After adjustment for all of these variables in a linear regression model, a significant difference was observed by site in global QoL score and the dimensions 'worry II'(beta 0 = 20.7, p < .00), 'treatment '(beta 0 = 66.8, p < .00) and communication II'(beta 0 = 45.8, p < .00). These dimensions are affected by the capacity of health professionals to provide clinical and psychological support to patients. Our results suggest that QoL of this patient population varied according the health center even adjusted by sociodemographics characteristics. Additional training of health professionals in psychological and clinical support could directly reduce patient apprehension about the disease its clinical complications.